Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Pacific Biosciences of CaliforniaCoherentBerkeley LightsBrukerQuanterix
SymbolNASDAQ:PACBNASDAQ:COHRNASDAQ:BLINASDAQ:BRKRNASDAQ:QTRX
Price Information
Current Price$31.53$268.04$47.93$67.65$61.09
52 Week RangeBuyHoldBuyHoldBuy
MarketRank™
Overall Score1.61.51.41.91.4
Analysis Score3.41.23.41.12.5
Community Score2.82.62.92.42.3
Dividend Score0.00.00.01.70.0
Ownership Score1.71.70.01.71.7
Earnings & Valuation Score0.01.90.62.50.6
Analyst Ratings
Consensus RecommendationBuyHoldBuyHoldBuy
Consensus Price Target$43.50$169.00$95.00$55.50$71.67
% Upside from Price Target37.96% upside-36.95% downside98.21% upside-17.96% downside17.31% upside
Trade Information
Market Cap$6.09 billion$6.56 billion$3.18 billion$10.25 billion$2.22 billion
Beta1.321.54N/A1.291.71
Average Volume4,758,249565,3361,132,851473,592438,231
Sales & Book Value
Annual Revenue$90.89 million$1.23 billionN/A$2.07 billion$56.73 million
Price / Sales66.995.34N/A4.9539.06
CashflowN/A$33.30 per shareN/A$2.39 per shareN/A
Price / CashN/A8.05N/A28.29N/A
Book Value$0.36 per share$38.23 per shareN/A$5.96 per share$4.59 per share
Price / Book87.587.01N/A11.3513.31
Profitability
Net Income$-84,130,000.00$-414,140,000.00N/A$197.20 million$-40,800,000.00
EPS($0.55)$1.44N/A$1.57($1.63)
Trailing P/E RatioN/AN/A0.0066.32N/A
Forward P/E RatioN/A38.79N/A39.33N/A
P/E GrowthN/AN/AN/A7.11N/A
Net Margins-57.25%-33.70%N/A8.04%-41.69%
Return on Equity (ROE)-101.30%3.41%N/A21.78%-22.37%
Return on Assets (ROA)-32.33%1.81%N/A6.99%-16.55%
Dividend
Annual PayoutN/AN/AN/A$0.16N/A
Dividend YieldN/AN/AN/A0.24%N/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/A10.19%N/A
Years of Consecutive Dividend GrowthN/AN/AN/A1 YearsN/A
Debt
Debt-to-Equity RatioN/A0.44%0.05%0.86%0.01%
Current Ratio1.84%4.52%11.41%2.67%7.65%
Quick Ratio1.72%2.93%10.87%1.65%7.18%
Ownership Information
Institutional Ownership Percentage84.85%91.82%26.96%65.89%71.60%
Insider Ownership Percentage11.60%0.62%N/A26.80%25.40%
Miscellaneous
Employees4124,8752307,400314
Shares Outstanding193.10 million24.46 million66.28 million151.57 million36.27 million
Next Earnings Date4/29/2021 (Confirmed)5/26/2021 (Estimated)5/11/2021 (Confirmed)5/5/2021 (Confirmed)5/4/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableNot Optionable
SourceHeadline
Insider Selling: Quanterix Co. (NASDAQ:QTRX) SVP Sells 1,667 Shares of StockInsider Selling: Quanterix Co. (NASDAQ:QTRX) SVP Sells 1,667 Shares of Stock
americanbankingnews.com - April 15 at 7:40 PM
Global Preventive Medicine Market 2021 Overview, Opportunities, In-Depth Analysis by 2025 : Novo Nordisk, Eli Lilly, Preventive Medical Health Care, Cancer Prevention Pharmaceuticals, Quanterix, Phoenix Medicine, US Preventive Medicine - Los Hijos de la MalincheGlobal Preventive Medicine Market 2021 Overview, Opportunities, In-Depth Analysis by 2025 : Novo Nordisk, Eli Lilly, Preventive Medical Health Care, Cancer Prevention Pharmaceuticals, Quanterix, Phoenix Medicine, US Preventive Medicine - Los Hijos de la Malinche
loshijosdelamalinche.com - April 15 at 8:26 AM
Powering Precision Health Founder Leads Conversation at the Precision Medicine Leaders Summit on Disrupting Precision Health with Next-Generation Proteomics - Business WirePowering Precision Health Founder Leads Conversation at the Precision Medicine Leaders Summit on Disrupting Precision Health with Next-Generation Proteomics - Business Wire
businesswire.com - April 12 at 6:01 PM
Global Biomarker Detection Systems Market Latest Analysis 2020 – Thermo Fisher Scientific, Quanterix, Agilent Technologies – ROUGH Magazine - ROUGH MagazineGlobal Biomarker Detection Systems Market Latest Analysis 2020 – Thermo Fisher Scientific, Quanterix, Agilent Technologies – ROUGH Magazine - ROUGH Magazine
rough.asia - April 12 at 1:00 PM
-$0.32 EPS Expected for Quanterix Co. (NASDAQ:QTRX) This Quarter-$0.32 EPS Expected for Quanterix Co. (NASDAQ:QTRX) This Quarter
americanbankingnews.com - April 10 at 12:12 PM
QUANTERIX CORP : Change in Directors or Principal Officers (form 8-K) - marketscreener.comQUANTERIX CORP : Change in Directors or Principal Officers (form 8-K) - marketscreener.com
marketscreener.com - April 9 at 7:30 PM
A List of 7 Proteomics Stocks For Investing in Proteins - NanalyzeA List of 7 Proteomics Stocks For Investing in Proteins - Nanalyze
nanalyze.com - April 8 at 12:56 PM
Vizgen Raises $37M in Series B Financing - GenomeWebVizgen Raises $37M in Series B Financing - GenomeWeb
genomeweb.com - April 8 at 12:35 AM
Do Traders Think Quanterix Corp (QTRX) Can Keep Climbing Tuesday? - InvestorsObserverDo Traders Think Quanterix Corp (QTRX) Can Keep Climbing Tuesday? - InvestorsObserver
investorsobserver.com - April 6 at 5:16 PM
Quanterix (NASDAQ:QTRX) Trading Up 7.2%Quanterix (NASDAQ:QTRX) Trading Up 7.2%
americanbankingnews.com - April 6 at 1:02 PM
Insider Selling: Quanterix Co. (NASDAQ:QTRX) General Counsel Sells 201 Shares of StockInsider Selling: Quanterix Co. (NASDAQ:QTRX) General Counsel Sells 201 Shares of Stock
americanbankingnews.com - April 5 at 5:50 PM
Quanterix Co. (NASDAQ:QTRX) CEO E Kevin Hrusovsky Sells 3,432 SharesQuanterix Co. (NASDAQ:QTRX) CEO E Kevin Hrusovsky Sells 3,432 Shares
americanbankingnews.com - April 5 at 4:46 PM
Index Falls Again in March, Led by 29 Percent Decline in Adaptive Biotech Stock | GenomeWeb - GenomeWebIndex Falls Again in March, Led by 29 Percent Decline in Adaptive Biotech Stock | GenomeWeb - GenomeWeb
genomeweb.com - April 2 at 12:55 AM
Neurological Biomarkers Market Business Growth Statistics and Key Players Insights By Quanterix Corp - PharmiWeb.comNeurological Biomarkers Market Business Growth Statistics and Key Players Insights By Quanterix Corp - PharmiWeb.com
pharmiweb.com - April 1 at 9:54 AM
Quanterix (NASDAQ:QTRX) Shares Gap Up to $54.66Quanterix (NASDAQ:QTRX) Shares Gap Up to $54.66
americanbankingnews.com - March 31 at 11:00 AM
Quanterix (NASDAQ:QTRX) Rating Increased to Hold at Zacks Investment ResearchQuanterix (NASDAQ:QTRX) Rating Increased to Hold at Zacks Investment Research
marketbeat.com - March 31 at 3:42 AM
Quanterix Simoa Technology Demonstrates Advancements in COVID-19 Research through Viral Antigen Measurements in Blood and Saliva Samples - Business WireQuanterix' Simoa Technology Demonstrates Advancements in COVID-19 Research through Viral Antigen Measurements in Blood and Saliva Samples - Business Wire
businesswire.com - March 26 at 6:21 PM
Quanterix’ Simoa Technology Demonstrates Advancements in COVID-19 Research through Viral Antigen Measurements in Blood and Saliva SamplesQuanterix’ Simoa Technology Demonstrates Advancements in COVID-19 Research through Viral Antigen Measurements in Blood and Saliva Samples
finance.yahoo.com - March 26 at 8:17 AM
Assessment of the Alzheimers Diagnostic Test Market, 2021-2025: QUANTERIX,F. HOFFMANN-LA ROCHE LTD – The Market Eagle - The Market EagleAssessment of the Alzheimers Diagnostic Test Market, 2021-2025: QUANTERIX,F. HOFFMANN-LA ROCHE LTD – The Market Eagle - The Market Eagle
themarketeagle.com - March 25 at 3:18 PM
Quanterix (NASDAQ:QTRX) Shares Gap Down to $60.33Quanterix (NASDAQ:QTRX) Shares Gap Down to $60.33
americanbankingnews.com - March 24 at 11:54 AM
Quanterix : Ultrasensitive quantification of plasma biomarkers is shaping the future of care for Alzheimers disease - Marketscreener.comQuanterix : Ultrasensitive quantification of plasma biomarkers is shaping the future of care for Alzheimer's disease - Marketscreener.com
marketscreener.com - March 22 at 3:09 PM
Quanterix Simoa Technology Accelerates Critical Plasma Biomarker Research Presented at the 15th International Conference on Parkinsons & Alzheimers Disease (AD/PDTM 2021) - Business WireQuanterix' Simoa Technology Accelerates Critical Plasma Biomarker Research Presented at the 15th International Conference on Parkinson's & Alzheimer's Disease (AD/PDTM 2021) - Business Wire
businesswire.com - March 17 at 7:45 PM
Quanterix’ Simoa Technology Accelerates Critical Plasma Biomarker Research Presented at the 15th International Conference on Parkinson’s & Alzheimer’s Disease (AD/PDTM 2021)Quanterix’ Simoa Technology Accelerates Critical Plasma Biomarker Research Presented at the 15th International Conference on Parkinson’s & Alzheimer’s Disease (AD/PDTM 2021)
finance.yahoo.com - March 17 at 7:45 PM
How Will the Market React to Quanterix Corp (QTRX) Stock Getting a Bullish Rating - InvestorsObserverHow Will the Market React to Quanterix Corp (QTRX) Stock Getting a Bullish Rating - InvestorsObserver
investorsobserver.com - March 12 at 9:39 PM
Do Analysts Agree Monday on Quanterix Corp (QTRX) Stocks Target Price? - InvestorsObserverDo Analysts Agree Monday on Quanterix Corp (QTRX) Stock's Target Price? - InvestorsObserver
investorsobserver.com - March 9 at 12:34 AM
(3/7/2021) QTRX Stock Has Strong Chance Of A Rise Over The Next Month After Declining 18% In The Last 5 Days. - Trefis(3/7/2021) QTRX Stock Has Strong Chance Of A Rise Over The Next Month After Declining 18% In The Last 5 Days. - Trefis
trefis.com - March 8 at 2:28 PM
DateCompanyBrokerageAction
2/12/2021Pacific Biosciences of CaliforniaMorgan StanleyBoost Price Target
2/11/2021Pacific Biosciences of CaliforniaCantor FitzgeraldBoost Price Target
2/11/2021Pacific Biosciences of CaliforniaPiper SandlerUpgrade
10/2/2020Pacific Biosciences of CaliforniaJPMorgan Chase & Co.Upgrade
12/18/2019Pacific Biosciences of CaliforniaPiper Jaffray CompaniesReiterated Rating
4/2/2019Pacific Biosciences of CaliforniaStephensDowngrade
1/4/2019Pacific Biosciences of CaliforniaCowenDowngrade
2/11/2021CoherentBenchmarkDowngrade
1/21/2021CoherentBerenberg BankDowngrade
1/20/2021CoherentBarclaysUpgrade
11/12/2020CoherentLongbow ResearchDowngrade
11/11/2020CoherentStifel NicolausDowngrade
9/14/2020CoherentVertical ResearchUpgrade
8/5/2020CoherentNeedham & Company LLCReiterated Rating
5/29/2020CoherentSusquehanna BancsharesReiterated Rating
4/24/2020CoherentThe Goldman Sachs GroupUpgrade
11/10/2020Berkeley LightsKeyCorpInitiated Coverage
8/11/2020Berkeley LightsWilliam BlairReiterated Rating
2/17/2021BrukerCitigroupBoost Price Target
2/5/2021BrukerWells Fargo & CompanyDowngrade
1/27/2021BrukerSVB LeerinkBoost Price Target
12/17/2020BrukerBTIG ResearchBoost Price Target
12/16/2020BrukerCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/16/2020BrukerSmith Barney CitigroupBoost Price Target
11/16/2020BrukerWolfe ResearchUpgrade
7/20/2020BrukerBank of AmericaBoost Price Target
5/1/2020BrukerCleveland ResearchDowngrade
4/28/2020BrukerUBS GroupLower Price Target
3/3/2021QuanterixCanaccord GenuityBoost Price Target
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.